Effect of EstroG-100 on menopausal symptoms
Researchers in Korea and the US studied EstroG-100 — a mixture of standardized extracts of Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas.
First, the details.
- 64 pre-, peri- and postmenopausal White Hispanic, White non-Hispanic, and African American women were randomly assigned to a treatment group for 12?weeks.
- EstroG-100
- Placebo group
- Changes in the Kupperman menopause index (evaluates the severity of menopausal symptoms), and vaginal dryness were measured.
- Neither the researchers nor patents were aware of the treatment given — double blind.
And, the results.
- The average Kupperman menopause index score was significantly reduced in the EstroG-100 group (30 to 11) compared with the placebo group (29 to 24) at week 12.
- Vasomotor symptoms, paresthesia (numbness), insomnia, nervousness, melancholia, vertigo, fatigue, and rheumatic pain were significantly improved in the EstroG-100 group vs the placebo group.
- Statistically significant improvement in vaginal dryness in the EstroG-100 group was also observed vs the placebo group.
The bottom line?
The authors concluded, “EstroG-100 significantly improved the menopausal symptoms of pre-, peri- and post-menopausal women without weight gain or any serious side effects.”
Cynanchum wilfordii is a perennial herb whose roots have been used in Korea to treat insomnia and anxiety. Phlomis umbrosa purportedly has protective effects on the liver and is used as a haemostatic and to treat athlete’s foot. Angelica gigas is used in Korea to treat “women’s diseases.”
This appears to be the first published study of EstroG.
9/7/11 23:02 JR
